ASLAN Pharmaceuticals Lim... (ASLN)
NASDAQ: ASLN
· Real-Time Price · USD
0.60
-0.10 (-14.27%)
At close: Jul 18, 2024, 10:00 PM
ASLAN Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | 12M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | 12M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -9.29M | -12.85M | -10.42M | -2.36M | -18.1M | -13.39M | -10.29M | -12.3M | -11.89M | -11.14M | -8.03M | -7.83M | -6.86M |
Interest Income | 1.74K | 10.11K | 1.41K | 68.91K | 324.55K | 224.02K | 86.64K | 41.37K | 2.42K | 42.00 | 20.00 | 20.00 | 137.00 |
Pretax Income | -9.92M | -13.47M | -9.68M | -1.83M | -19.11M | -14.4M | -10.91M | -13.03M | -12.94M | -9.14M | -8.55M | -5.45M | -6.97M |
Net Income | -9.92M | -13.51M | -9.71M | -1.89M | -19.11M | -14.48M | -10.93M | -12.89M | -12.9M | -9.14M | -8.55M | -5.43M | -6.72M |
Selling & General & Admin | 3.4M | 3.25M | 3.18M | 2.77M | 4.05M | 2.71M | 2.32M | 2.32M | 2.54M | 2.17M | 2.77M | 3.79M | 3.11M |
Research & Development | 5.9M | 9.6M | 7.24M | 11.6M | 14.06M | 10.69M | 7.98M | 9.98M | 9.36M | 8.96M | 5.26M | 4.04M | 3.75M |
Other Expenses | 36.03K | n/a | n/a | n/a | n/a | n/a | n/a | -126.56K | n/a | n/a | n/a | -21.39K | n/a |
Operating Expenses | 9.29M | 12.85M | 10.42M | 14.36M | 18.1M | 13.39M | 10.29M | 12.17M | 11.89M | 11.14M | 8.03M | 7.81M | 6.86M |
Interest Expense | 666.07K | 992.86K | 1.13M | 1.13M | 1.07M | 778.26K | 937.11K | 877.3K | 1.08M | 747.9K | 498.15K | 203.43K | 411.47K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.29M | 12.85M | 10.42M | 14.36M | 18.1M | 13.39M | 10.29M | 12.17M | 11.89M | 11.14M | 8.03M | 7.81M | 6.86M |
Income Tax Expense | n/a | 39.92K | 28K | 58.16K | 6.59K | 79.38K | 19.84K | -142.87K | -39.88K | n/a | -80.1K | -19.29K | 161.67K |
Shares Outstanding (Basic) | 746.82K | 691.32K | 688.09K | 657.72K | 593.13K | 557.96K | 557.96K | 557.96K | 557.96K | 553.52K | 557.31K | 556.94K | 411.46K |
Shares Outstanding (Diluted) | 746.82K | 691.32K | 688.09K | 657.72K | 593.13K | 557.96K | 557.96K | 557.96K | 557.96K | 556.85K | 557.31K | 557.31K | 411.46K |
EPS (Basic) | -13.25 | -19.5 | -14 | -2.75 | -32.25 | -26 | -19.5 | -23 | -23 | -16.5 | -15.25 | -9.75 | -16.25 |
EPS (Diluted) | -13.25 | -19.5 | -14 | -2.75 | -32.25 | -26 | -19.5 | -23 | -23 | -16.5 | -15.25 | -9.75 | -16.25 |
EBITDA | -9.25M | -12.48M | -8.55M | -699.9K | -18.03M | -13.62M | -9.97M | -12.16M | -11.85M | -10.7M | -8.06M | -5.23M | -6.56M |
EBIT | -9.25M | -12.48M | -8.55M | -702.85K | -18.03M | -13.62M | -9.97M | -12.16M | -11.85M | -8.2M | -8.06M | -5.24M | -6.56M |
Depreciation & Amortization | 43.28K | 43.81K | 1.87M | 1.66M | 72.27K | -229.87K | 322.1K | 142.87K | 39.88K | 438.12K | -26.1K | 2.61M | 297.32K |